EZH2 and atherosclerosis: A PCSK9 inhibitor was found to mitigate atherosclerosis by modulating the small nucleolar RNA host gene 16 (SNHG16)/enhancer of zeste homolog 2 (EZH2)/TNF receptor-associated factor 5 (TRAF5) axis, thereby restraining the migration, proliferation and formation of foam cells by VSMCs [60].